News on Wellness

GlaxoSmithKline to Fund $200 Million on Research for Non-Communicable Diseases


According to the company statement, GlaxoSmithKline the British pharmaceutical giant is planning to invest over $200 million in Africa towards research. This drive will look for treatment of non communicable diseases as against the infectious diseases. According to the statement, the African continent has been concentrated only for infectious diseases in form of aid; these non communicable diseases have been ignored.


According to spokesperson, the funding is focused on the sub Saharan Africa. The pharmaceutical giant already has 3 factories in this area in which there are about 1500 people working. The funded money will be used to build 5 factories and fund for research and development. Though infectious diseases are the major problem in Africa, this lab will focus on the non communicable illness and the centrepiece will be the located in Stevenage, England.

Further, the spokesperson added that the harbour will act as a collaboration Centre, which will get information from the Glaxo scientific working on different projects on the non communicable diseases like cardiovascular diseases and cancer.

In an interview with Shots, Mr. Andrew Witty, the CEO of the company, informed that the lab is going to be the most important part of the research in the long run. He also added that this is the 1st time any pharmaceutical company is concentrating on non communicable diseases as the issue of infectious diseases have always been highlighted due to its seriousness. He further added that the shift from infectious diseases to non communicable diseases is due to increasing the awareness of vaccination and also management of other deadly diseases like HIV.

He added that a certain amount of control has been gained and hence it is time to start concentrating on the other important diseases which are being clouded. In fact, the report from Institute of Health Metrics and Evaluation, as well as the World Bank shows that there is commendable progress in the infectious diseases issue.

Mr. Evans of World Bank has reported that the rates of infectious decisions are coming down drastically in Africa. Though a lot of improvement is yet needed, this is a good sign according to him. Supporting Mr Evan’s statement, Mr Witty added that the prospect of business is increasing and though success is not guaranteed, there is nothing wrong in being ambitious.

Leave a Reply

Your email address will not be published. Required fields are marked *